Investor Presentaiton

Executive Summary Transaction summary Denmark Facility overview Strategic rationale Little Green Pharma Ltd ("LGP") has acquired 100% of the issued shares of Canopy Growth Denmark A.p.S ("LGP Denmark") which owns a medicinal cannabis production facility in Denmark (EU) ("Denmark Facility") Acquisition price C$20 million (~A$21.4m¹) World class cannabis cultivation and manufacturing facility in Denmark Meets GACP cultivation standards and holds EU-recognised GMP manufacturing licence Capable of producing >20 tonnes p.a. biomass including ~12 tonnes p.a. of dried cannabis flower Accelerates LGP's current planned capacity expansion and market penetration by two years Immediately increases LGP's cultivation capacity to >23 tonnes of biomass and ~13.5 tonnes per annum of dried cannabis flower (up from ~3.0 tonnes and ~1.5 tonnes, respectively) Acquisition consistent with LGP's EU expansion strategy and clear strategic fit with LGP's existing operations and capabilities Provides platform to leverage Company's early mover advantage and brand equity in key EU markets Consistent with LGP's strategy of acquiring or building adequate capacity to meet market demand and avoiding over-capitalisation Acquisition consideration compares very favourably with facility investment to date Maintains LGP's sole focus on medicinal cannabis LGP Group will benefit from internally sharing best-practice cultivation, manufacturing, and pharmaceutical practices and expertise 1. CADAUD: 1.07 little green pharma

View entire presentation